Characterization and comparison of the properties of sarcoma cell lines in vitro and in vivo

被引:17
作者
Mills, Joslyn [2 ]
Matos, Tulio [2 ]
Charytonowicz, Elizabeth [2 ]
Hricik, Todd [2 ]
Castillo-Martin, Mireia [2 ]
Remotti, Fabrizio [2 ]
Lee, Francis Y. [3 ]
Matushansky, Igor [1 ]
机构
[1] Columbia Univ, Dept Med, Div Med Oncol, New York, NY 10032 USA
[2] Columbia Univ, Dept Pathol, New York, NY 10032 USA
[3] Columbia Univ, Dept Orthoped, New York, NY 10032 USA
来源
HUMAN CELL | 2009年 / 22卷 / 04期
关键词
cell line; properties; sarcoma; SOFT-TISSUE SARCOMAS; GEMCITABINE; DOCETAXEL; ECTEINASCIDIN-743; SENSITIVITY; TRABECTEDIN; METASTASIS; PATHWAY; AGENT; P53;
D O I
10.1111/j.1749-0774.2009.00073.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
To expand the available tools for investigating human sarcomas, we characterized the primary properties of 22 common, uncommon, and newly characterized sarcoma cell lines representing eight different histological subtypes. Throughout the characterization process we noticed that in vitro markers and assays are poor indicators of tumorigenicity and that generated xenografts often bear little resemblance to the original histopathology. In vitro properties examined included morphology, proliferation rate, cell cycle characteristics, invasiveness, and immunohistochemical expression of p53 and phospho-AKT. In vivo properties examined included days to tumor formation in NOD/SCID mice, xenograft morphology in several locations and immunohistochemical expression of Ki67, p53 and phospho-AKT. We believe that such an in depth comparison of a large cohort of sarcoma cell lines will be useful in both designing and interpreting experiments aimed at elucidating both the molecular biology and efficacy of therapeutic agents in sarcomas. However, that data generated also suggests a small set of sarcoma cell lines may be inappropriate for generalizations regarding biological behavior of specific sarcoma subtypes. Integration of functional genomics or other more sophisticated assays of cell lines may help bridge the differences in vitro and in vivo.
引用
收藏
页码:85 / 93
页数:9
相关论文
共 21 条
[1]   Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines [J].
Ando, T ;
Ichikawa, J ;
Okamoto, A ;
Tasaka, K ;
Nakao, A ;
Hamada, Y .
JOURNAL OF ORTHOPAEDIC RESEARCH, 2005, 23 (04) :964-969
[2]  
[Anonymous], APPLIED STATISTICS
[3]  
Chambers J.M., 1992, STAT MODELS, p96
[4]   Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin [J].
Graat, H. C. A. ;
Witlox, M. A. ;
Schagen, F. H. E. ;
Kaspers, G. J. L. ;
Helder, M. N. ;
Bras, J. ;
Schaap, G. R. ;
Gerritsen, W. R. ;
Wuisman, P. I. J. M. ;
van Beusechem, V. W. .
BRITISH JOURNAL OF CANCER, 2006, 94 (12) :1837-1844
[5]   Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study [J].
Grosso, Federica ;
Jones, Robin L. ;
Demetri, George D. ;
Judson, Ian R. ;
Blay, Jean-Yves ;
Le Cesne, Axel ;
Sanfilippo, Roberta ;
Casieri, Paola ;
Collini, Paola ;
Dileo, Palma ;
Spreafico, Carlo ;
Stacchiotti, Silvia ;
Tamborini, Elena ;
Tercero, Juan Carlos ;
Jimeno, Jose ;
D'Incalci, Maurizio ;
Gronchi, Alessandro ;
Fletcher, Jonathan A. ;
Pilotti, Silvana ;
Casali, Paola G. .
LANCET ONCOLOGY, 2007, 8 (07) :595-602
[6]   The hallmarks of cancer [J].
Hanahan, D ;
Weinberg, RA .
CELL, 2000, 100 (01) :57-70
[7]  
Hastie TJ, 1992, STAT MODELS S, P196
[8]   The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas [J].
Hernando, Eva ;
Charytonowicz, Elizabeth ;
Dudas, Maria E. ;
Menendez, Silvia ;
Matushansky, Igor ;
Mills, Joslyn ;
Socci, Nicholas D. ;
Behrendt, Nille ;
Ma, Li ;
Maki, Robert G. ;
Pandolfi, Pier Paolo ;
Cordon-Cardo, Carlos .
NATURE MEDICINE, 2007, 13 (06) :748-753
[9]  
Heslin MJ, 1998, CANCER-AM CANCER SOC, V83, P490, DOI 10.1002/(SICI)1097-0142(19980801)83:3<490::AID-CNCR18>3.0.CO
[10]  
2-R